Last reviewed · How we verify
isoniazid , randomized, open label
Isoniazid inhibits the synthesis of mycolic acid in Mycobacterium tuberculosis by inhibiting the enzyme enoyl-acyl carrier protein reductase (InhA).
Isoniazid inhibits the synthesis of mycolic acid in Mycobacterium tuberculosis by inhibiting the enzyme enoyl-acyl carrier protein reductase (InhA). Used for Treatment of tuberculosis, Prophylaxis of tuberculosis in individuals exposed to M. tuberculosis.
At a glance
| Generic name | isoniazid , randomized, open label |
|---|---|
| Sponsor | National Taiwan University Hospital |
| Drug class | Antitubercular agent |
| Target | InhA |
| Modality | Small molecule |
| Therapeutic area | Infectious disease |
| Phase | Phase 3 |
Mechanism of action
This inhibition disrupts the bacterial cell wall synthesis, ultimately leading to the death of the bacteria. Isoniazid is a prodrug that requires activation by the enzyme catalase-peroxidase (KatG) to exert its antibacterial effect.
Approved indications
- Treatment of tuberculosis
- Prophylaxis of tuberculosis in individuals exposed to M. tuberculosis
Common side effects
- Peripheral neuropathy
- Hepatotoxicity
- Gastrointestinal disturbances
Key clinical trials
- Safety and Tolerability of Metformin in People With Tuberculosis (TB) and Human Immunodeficiency Virus (HIV) (PHASE2)
- Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis (PHASE2)
- Phase 2a Trial of Alpibectir Plus Ethionamide for Tuberculosis Meningitis (PHASE2)
- Ultra-Short Course Bedaquiline, Clofazimine, Pyrazinamide and Delamanid Versus Standard Therapy for Drug-Susceptible TB (PHASE2)
- Pharmacokinetics of Antituberculosis Drugs in Breastfeeding Women (PHASE1)
- Trial of a Six-Month Regimen of High-Dose Rifampicin, High-Dose Isoniazid, Linezolid, and Pyrazinamide Versus a Standard Nine-Month Regimen for the Treatment of Adults and Adolescents With Tuberculous Meningitis (PHASE2)
- PanACEA - STEP2C -01 (PHASE2)
- ATORvastatin in Pulmonary TUBerculosis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: